Literature DB >> 11408246

Comparative in vitro activity of ABT-773, a novel antibacterial ketolide.

A M Nilius1, M H Bui, L Almer, D Hensey-Rudloff, J Beyer, Z Ma, Y S Or, R K Flamm.   

Abstract

The in vitro activities of ABT-773, erythromycin, clarithromycin, and azithromycin were compared. ABT-773 was the most active compound against macrolide-susceptible Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Enterococcus spp. and multidrug-resistant Streptococcus pneumoniae. It also had good activity against gram-negative and atypical respiratory tract pathogens and Helicobacter pylori.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11408246      PMCID： PMC90623          DOI： 10.1128/AAC.45.7.2163-2168.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  In vitro activity of ABT 773, a new ketolide antibiotic, against Chlamydia pneumoniae.

Authors:  S Strigl; P M Roblin; T Reznik; M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

2.  Design, synthesis, and antimicrobial activity of 6-O-substituted ketolides active against resistant respiratory tract pathogens.

Authors:  Y S Or; R F Clark; S Wang; D T Chu; A M Nilius; R K Flamm; M Mitten; P Ewing; J Alder; Z Ma
Journal:  J Med Chem       Date:  2000-03-23       Impact factor: 7.446

3.  In vitro activity of ABT-773, a new ketolide, against recent clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.

Authors:  A B Brueggemann; G V Doern; H K Huynh; E M Wingert; P R Rhomberg
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

4.  New research in macrolides and ketolides since 1997.

Authors:  A Bryskier
Journal:  Expert Opin Investig Drugs       Date:  1999-08       Impact factor: 6.206

5.  Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America.

Authors:  J G Bartlett; R F Breiman; L A Mandell; T M File
Journal:  Clin Infect Dis       Date:  1998-04       Impact factor: 9.079

6.  Studies of the novel ketolide ABT-773: transport, binding to ribosomes, and inhibition of protein synthesis in Streptococcus pneumoniae.

Authors:  J O Capobianco; Z Cao; V D Shortridge; Z Ma; R K Flamm; P Zhong
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

7.  Rapidly growing mycobacteria: testing of susceptibility to 34 antimicrobial agents by broth microdilution.

Authors:  J M Swenson; C Thornsberry; V A Silcox
Journal:  Antimicrob Agents Chemother       Date:  1982-08       Impact factor: 5.191

8.  In vitro activity of A-56268 (TE-031) and four other antimicrobial agents against Chlamydia trachomatis.

Authors:  J Segreti; H A Kessler; K S Kapell; G M Trenholme
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

9.  In vitro and in vivo evaluations of A-80556, a new fluoroquinolone.

Authors:  J J Clement; S K Tanaka; J Alder; C Vojtko; J Beyer; D Hensey; N Ramer; D McDaniel; D T Chu
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

10.  Susceptibility of the Lyme disease spirochete to seven antimicrobial agents.

Authors:  S E Johnson; G C Klein; G P Schmid; J C Feeley
Journal:  Yale J Biol Med       Date:  1984 Jul-Aug
View more
  9 in total

1.  Activities of cethromycin and telithromycin against recent North American isolates of Streptococcus pneumoniae.

Authors:  James H Jorgensen; Sharon A Crawford; M Leticia McElmeel; Cynthia G Whitney
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

2.  Binding site of macrolide antibiotics on the ribosome: new resistance mutation identifies a specific interaction of ketolides with rRNA.

Authors:  G Garza-Ramos; L Xiong; P Zhong; A Mankin
Journal:  J Bacteriol       Date:  2001-12       Impact factor: 3.490

3.  Cethromycin versus clarithromycin for community-acquired pneumonia: comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies.

Authors:  Marci L English; Christine E Fredericks; Nancy A Milanesio; Nestor Rohowsky; Ze-Qi Xu; Tuah R J Jenta; Michael T Flavin; David A Eiznhamer
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

4.  Efficacies of ABT-773, a new ketolide, against experimental bacterial infections.

Authors:  M J Mitten; J Meulbroek; M Nukkala; L Paige; K Jarvis; A Oleksijew; A Tovcimak; L Hernandez; J D Alder; P Ewing; Y S Or; Z Ma; A M Nilius; K Mollison; R K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

5.  Postantibiotic effects of ABT-773 and amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae.

Authors:  M M Neuhauser; J L Prause; L H Danziger; S L Pendland
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

Review 6.  The ketolides: a critical review.

Authors:  George G Zhanel; Michael Walters; Ayman Noreddin; Lavern M Vercaigne; Aleksandra Wierzbowski; John M Embil; Alfred S Gin; Stephen Douthwaite; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

7.  Impact of cethromycin (ABT-773) therapy on microbiological, histologic, immunologic, and respiratory indices in a murine model of Mycoplasma pneumoniae lower respiratory infection.

Authors:  Ana María Ríos; Asunción Mejías; Susana Chávez-Bueno; Mónica Fonseca-Aten; Kathy Katz; Jeanine Hatfield; Ana María Gómez; Hasan S Jafri; George H McCracken; Octavio Ramilo; Robert Doug Hardy
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

8.  In vitro activities of ABT-773 and other antimicrobials against human mycoplasmas.

Authors:  Ken B Waites; Donna M Crabb; Lynn B Duffy
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

9.  Activities of ABT-773 against Listeria monocytogenes and coryneform bacteria of clinical interest.

Authors:  María del Carmen Conejo; Luis Martínez-Martínez; Alvaro Pascual; Ana Isabel Suárez; Evelio J Perea
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.